Navigation Links
Scioderm to Present at 32nd Annual J.P. Morgan Healthcare Conference
Date:1/7/2014

DURHAM, N.C., Jan. 7, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that Dr. Robert Ryan, President and Chief Executive Officer of Scioderm, was invited to present at the 32nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. Pacific Standard Time (10:30 a.m. EST) on Thursday, January 16, 2014 in the Elizabethan C/D room of the Westin St. Francis hotel.

Dr. Ryan will discuss the company's lead investigational therapy, SD-101, currently in late stage clinical development for the treatment of skin blistering and lesions associated with inherited Epidermolysis Bullosa, a rare orphan pediatric disease.   SD-101 for the treatment of EB has been granted orphan drug designation in the US and in December 2013 received a positive opinion by the Committee for Orphan Medicinal Products (COMP) in the EU. 

About Scioderm, Inc.

Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. The company is headquartered in Durham, North Carolina. In 2013, Scioderm, Inc. was the first biotech to receive "Breakthrough Therapy" designation for its lead product, SD-101, from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with Epidermolysis Bullosa. In addition, Scioderm was recently selected as  a 2013 "Fierce Top 15" company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry.  Additional information about Scioderm can be found at www.sderm.com

About SD-101

SD-101 is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. An open-label Phase II study was conducted previously in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB.  The primary outcome measurements were assessment of target wound reduction and closure, and reduction in body surface area (BSA) coverage of blisters and lesions.  In the clinical trial, SD-101 application resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in BSA coverage of blisters and lesions after 3 months of daily treatment.   SD-101 was well tolerated by the children, with daily administration up to 3 months.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks.  Actual results may differ materially from those projected.  These forward-looking statements represent our judgment as of the date of the release.  Scioderm disclaims any intent or obligation to update these forward-looking statements.

Investor and Media Contact

Robert Coull
Chief Operating Officer
robert.coull@sderm.com
(919)-824-2594


'/>"/>
SOURCE Scioderm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Scioderm, Inc. Named a 2013 "Fierce Top 15" Company by FierceBiotech
2. Scioderm Appoints Orphan Product Executives to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
7. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
8. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
11. PRA Expert to Present at Pharmacovigilance Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
Breaking Biology News(10 mins):